Power Law company profile

Onyx Pharmaceuticals

Biotech & Life Sciences · South San Francisco, United States · Founded 1992 Decacorn

Biopharmaceutical company committed to improving the lives of people with cancer

Headcount

100–500

Current team size

Unlock exact value

Featured in Decacorn$10B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

4 investors on Onyx Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

Sequoia

Series B+ 3 investors entered at this stage

Federated Hermes

Domain Associates

OrbiMed

Onyx Pharmaceuticals mafia

Startups founded by Onyx Pharmaceuticals alumni

Former Onyx Pharmaceuticals employees who went on to start their own companies. Sorted by Dealroom signal score.

BridgeBioEst. 2014

Frank McCormickUnited States

Signal score90

HelixEst. 2015

Justin KaoUnited States

Signal score82

IlluminaEst. 1998

Joel Martin,Ph.D.United States

Signal score72

Cadence HealthEst. 2016

Samantha MillerUnited States

4D Molecular TherapeuticsEst. 2013

David KirnUnited States

Signal score66

Book a demo to explore the full alumni network →

Global footprint

Where Onyx Pharmaceuticals has talent and traffic

Workforce by country

7 countries with
team presence

🇺🇸 United States79.5%

🇨🇦 Canada6.8%

🇬🇧 United Kingdom4.5%

🇨🇭 Switzerland2.3%

🇵🇰 Pakistan2.3%

Top 5 of 7 shown

Patent intelligence

$105M patent portfolio · 38 active families

Estimated portfolio value

$105M

7.4× smaller than top peer BioNTech ($780M)

38 active patent families

Where Onyx Pharmaceuticals innovates Molecular biologyEnzyme inhibitionPeptideAziridineHeteroatom

Where Onyx Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Onyx Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Onyx Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Onyx Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Onyx Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles